Gene Editing Com-COV 3 study focuses on assessing a third dose booster vaccination for young people aged 12 to 15 Posted on June 7, 2022 by Editorial Staff The Com-COV 3 study has been commissioned through the NIHR and backed by £2.8 million government funding, with support from both the Vaccine Taskforce and National Institute for Health and Care Research (NIHR). Share on FacebookTweetFollow us Editorial Staff FDA advisers recommend authorization of Novavax’s Covid-19 vaccine Traditional methods of testing may not be enough to detect low levels of high-risk salmonella